Analysis of Mesencephalic Astrocyte-derived Neurotrophic Factor in Multiple Myeloma.
Amandine Dernoncourt, Chloe Sauzay, Jean Schmidt, Christophe Louandre, Cathy Gomila, Pierre Duhaut, Yves-Edouard Herpe, Zuzana Saidak, Antoine Galmiche, Valery Salle
Author Information
Amandine Dernoncourt: Department of Internal Medicine and RECIF, Amiens-Picardie University Medical Center, Amiens, France; dernoncourt.amandine@chu-amiens.fr.
Chloe Sauzay: Laboratory of Biochemistry and Team CHIMERE, EA 7516, Amiens-Picardie University Medical Center, Amiens, France.
Jean Schmidt: Department of Internal Medicine and RECIF, Amiens-Picardie University Medical Center, Amiens, France.
Christophe Louandre: Laboratory of Biochemistry and Team CHIMERE, EA 7516, Amiens-Picardie University Medical Center, Amiens, France.
Cathy Gomila: Laboratory of Biochemistry and Team CHIMERE, EA 7516, Amiens-Picardie University Medical Center, Amiens, France.
Pierre Duhaut: Department of Internal Medicine and RECIF, Amiens-Picardie University Medical Center, Amiens, France.
Yves-Edouard Herpe: Biobank of Picardie, Amiens-Picardie University Medical Center, Amiens, France.
Zuzana Saidak: Laboratory of Molecular Oncobiology, Center of Human Biology, Amiens-Picardie University Medical Center, Amiens, France.
Antoine Galmiche: Laboratory of Biochemistry and Team CHIMERE, EA 7516, Amiens-Picardie University Medical Center, Amiens, France.
Valery Salle: Department of Internal Medicine and RECIF, Amiens-Picardie University Medical Center, Amiens, France.
BACKGROUND/AIM: Multiple myeloma (MM) is characterized by high production of immunoglobulins resulting in a constant source of endoplasmic reticulum (ER)-stress. Mesencephalic astrocyte-derived neurotrophic factor (MANF) was identified as a possible circulating biomarker that could help in monitoring ER-stress mediated diseases. MATERIALS AND METHODS: To assess the relevance of MANF in MM, we performed in silico and in vitro analysis in malignant cell lines including the myeloma cell line RPMI 8226. Serum MANF concentration was compared between healthy subjects (n=60), patients with MM (n=68), or those with monoclonal gammopathy of undetermined significance (MGUS) (n=73). RESULTS: MANF mRNA expression was upregulated in the RPMI 8226 cell line, and higher secretion of MANF was measured in RPMI 8226 supernatant. Serum MANF levels were not significantly different between MM or MGUS patients and those in age- and sex-matched healthy controls. CONCLUSION: MANF was not validated as a biomarker of interest in MM patients. Its potential implication in myeloma pathogenesis should be investigated.
